nodes	percent_of_prediction	percent_of_DWPC	metapath
Zileuton—EPHX2—Sorafenib—thyroid cancer	0.628	0.74	CbGbCtD
Zileuton—UGT1A9—Sorafenib—thyroid cancer	0.132	0.156	CbGbCtD
Zileuton—CYP1A2—Sorafenib—thyroid cancer	0.0246	0.0289	CbGbCtD
Zileuton—CYP2C9—Sorafenib—thyroid cancer	0.0221	0.0261	CbGbCtD
Zileuton—CYP3A4—Vandetanib—thyroid cancer	0.0214	0.0251	CbGbCtD
Zileuton—ALOX5—Synthesis of Lipoxins (LX)—HPGD—thyroid cancer	0.0166	0.175	CbGpPWpGaD
Zileuton—CYP3A4—Sorafenib—thyroid cancer	0.0129	0.0152	CbGbCtD
Zileuton—ALOX5—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.0112	0.118	CbGpPWpGaD
Zileuton—CYP3A4—Doxorubicin—thyroid cancer	0.00781	0.0092	CbGbCtD
Zileuton—EPHX2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00546	0.0576	CbGpPWpGaD
Zileuton—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00485	0.0512	CbGpPWpGaD
Zileuton—White blood cell count decreased—Vandetanib—thyroid cancer	0.00451	0.0892	CcSEcCtD
Zileuton—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00365	0.0385	CbGpPWpGaD
Zileuton—ALOX5—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00304	0.032	CbGpPWpGaD
Zileuton—EPHX2—Metapathway biotransformation—CHST14—thyroid cancer	0.00249	0.0262	CbGpPWpGaD
Zileuton—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00198	0.0209	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—LGALS3—thyroid cancer	0.00157	0.0165	CbGpPWpGaD
Zileuton—Tiaprofenic acid—PTGS2—thyroid cancer	0.00149	1	CrCbGaD
Zileuton—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00132	0.0139	CbGpPWpGaD
Zileuton—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00131	0.0259	CcSEcCtD
Zileuton—Urinary tract infection—Vandetanib—thyroid cancer	0.00122	0.0241	CcSEcCtD
Zileuton—Conjunctivitis—Vandetanib—thyroid cancer	0.00122	0.0241	CcSEcCtD
Zileuton—LTB4R—GPCR ligand binding—CALCB—thyroid cancer	0.00119	0.0125	CbGpPWpGaD
Zileuton—Sinusitis—Vandetanib—thyroid cancer	0.00118	0.0233	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—CDK1—thyroid cancer	0.00107	0.0113	CbGpPWpGaD
Zileuton—UGT1A9—PPAR Alpha Pathway—CDK1—thyroid cancer	0.00106	0.0112	CbGpPWpGaD
Zileuton—Abdominal pain upper—Sorafenib—thyroid cancer	0.001	0.0198	CcSEcCtD
Zileuton—UGT1A9—PPAR Alpha Pathway—RXRA—thyroid cancer	0.000985	0.0104	CbGpPWpGaD
Zileuton—ALOX5—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000981	0.0103	CbGpPWpGaD
Zileuton—EPHX2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00098	0.0103	CbGpPWpGaD
Zileuton—UGT1A9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000835	0.0088	CbGpPWpGaD
Zileuton—Chest pain—Vandetanib—thyroid cancer	0.000834	0.0165	CcSEcCtD
Zileuton—Arthralgia—Vandetanib—thyroid cancer	0.000834	0.0165	CcSEcCtD
Zileuton—Jaundice—Sorafenib—thyroid cancer	0.000825	0.0163	CcSEcCtD
Zileuton—LTB4R—trachea—thyroid cancer	0.000808	0.209	CbGeAlD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000781	0.00823	CbGpPWpGaD
Zileuton—UGT1A9—Metapathway biotransformation—CHST14—thyroid cancer	0.000736	0.00776	CbGpPWpGaD
Zileuton—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000729	0.0144	CcSEcCtD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000724	0.00762	CbGpPWpGaD
Zileuton—Insomnia—Vandetanib—thyroid cancer	0.000723	0.0143	CcSEcCtD
Zileuton—Dyspepsia—Vandetanib—thyroid cancer	0.000704	0.0139	CcSEcCtD
Zileuton—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000693	0.0073	CbGpPWpGaD
Zileuton—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000691	0.0137	CcSEcCtD
Zileuton—Constipation—Vandetanib—thyroid cancer	0.000684	0.0135	CcSEcCtD
Zileuton—Pain—Vandetanib—thyroid cancer	0.000684	0.0135	CcSEcCtD
Zileuton—LTB4R—GPCR downstream signaling—CALCB—thyroid cancer	0.000673	0.00709	CbGpPWpGaD
Zileuton—Liver injury—Epirubicin—thyroid cancer	0.000664	0.0131	CcSEcCtD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000662	0.00698	CbGpPWpGaD
Zileuton—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.000655	0.0069	CbGpPWpGaD
Zileuton—LTB4R—thyroid gland—thyroid cancer	0.000639	0.165	CbGeAlD
Zileuton—Body temperature increased—Vandetanib—thyroid cancer	0.000632	0.0125	CcSEcCtD
Zileuton—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.000615	0.0122	CcSEcCtD
Zileuton—Liver injury—Doxorubicin—thyroid cancer	0.000615	0.0122	CcSEcCtD
Zileuton—LTB4R—Signaling by GPCR—CALCB—thyroid cancer	0.000611	0.00644	CbGpPWpGaD
Zileuton—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000598	0.0063	CbGpPWpGaD
Zileuton—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000592	0.00624	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000579	0.0061	CbGpPWpGaD
Zileuton—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000569	0.0113	CcSEcCtD
Zileuton—Pruritus—Vandetanib—thyroid cancer	0.000566	0.0112	CcSEcCtD
Zileuton—Neck pain—Epirubicin—thyroid cancer	0.000566	0.0112	CcSEcCtD
Zileuton—Arthralgia—Sorafenib—thyroid cancer	0.000563	0.0111	CcSEcCtD
Zileuton—Myalgia—Sorafenib—thyroid cancer	0.000563	0.0111	CcSEcCtD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000563	0.00593	CbGpPWpGaD
Zileuton—Vaginal inflammation—Epirubicin—thyroid cancer	0.000559	0.0111	CcSEcCtD
Zileuton—LTB4R—GPCR ligand binding—TSHR—thyroid cancer	0.000551	0.00581	CbGpPWpGaD
Zileuton—Diarrhoea—Vandetanib—thyroid cancer	0.000547	0.0108	CcSEcCtD
Zileuton—ALOX5—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000545	0.00575	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—MINPP1—thyroid cancer	0.00054	0.00569	CbGpPWpGaD
Zileuton—Dizziness—Vandetanib—thyroid cancer	0.000529	0.0105	CcSEcCtD
Zileuton—Vaginal infection—Epirubicin—thyroid cancer	0.000528	0.0104	CcSEcCtD
Zileuton—Neck pain—Doxorubicin—thyroid cancer	0.000523	0.0104	CcSEcCtD
Zileuton—Vaginal inflammation—Doxorubicin—thyroid cancer	0.000517	0.0102	CcSEcCtD
Zileuton—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000513	0.0054	CbGpPWpGaD
Zileuton—Vomiting—Vandetanib—thyroid cancer	0.000509	0.0101	CcSEcCtD
Zileuton—Rash—Vandetanib—thyroid cancer	0.000504	0.00998	CcSEcCtD
Zileuton—Dermatitis—Vandetanib—thyroid cancer	0.000504	0.00997	CcSEcCtD
Zileuton—Headache—Vandetanib—thyroid cancer	0.000501	0.00992	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—PTGS2—thyroid cancer	0.000493	0.0052	CbGpPWpGaD
Zileuton—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000492	0.00973	CcSEcCtD
Zileuton—Hypertonia—Epirubicin—thyroid cancer	0.00049	0.0097	CcSEcCtD
Zileuton—Vaginal infection—Doxorubicin—thyroid cancer	0.000488	0.00966	CcSEcCtD
Zileuton—Lymphadenopathy—Epirubicin—thyroid cancer	0.000475	0.00941	CcSEcCtD
Zileuton—Nausea—Vandetanib—thyroid cancer	0.000475	0.0094	CcSEcCtD
Zileuton—Dyspepsia—Sorafenib—thyroid cancer	0.000475	0.0094	CcSEcCtD
Zileuton—EPHX2—thyroid gland—thyroid cancer	0.00047	0.122	CbGeAlD
Zileuton—LTB4R—GPCR ligand binding—PTCH1—thyroid cancer	0.000468	0.00494	CbGpPWpGaD
Zileuton—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000466	0.00922	CcSEcCtD
Zileuton—Pain—Sorafenib—thyroid cancer	0.000461	0.00913	CcSEcCtD
Zileuton—Constipation—Sorafenib—thyroid cancer	0.000461	0.00913	CcSEcCtD
Zileuton—EPHX2—Metabolism—NDUFA13—thyroid cancer	0.000459	0.00484	CbGpPWpGaD
Zileuton—Hypertonia—Doxorubicin—thyroid cancer	0.000453	0.00897	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—CCND1—thyroid cancer	0.000446	0.0047	CbGpPWpGaD
Zileuton—UGT1A9—PPAR Alpha Pathway—CCND1—thyroid cancer	0.000442	0.00466	CbGpPWpGaD
Zileuton—Lymphadenopathy—Doxorubicin—thyroid cancer	0.00044	0.00871	CcSEcCtD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000434	0.00458	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—CHST14—thyroid cancer	0.000431	0.00455	CbGpPWpGaD
Zileuton—Urticaria—Sorafenib—thyroid cancer	0.000429	0.00848	CcSEcCtD
Zileuton—LTB4R—GPCR ligand binding—SST—thyroid cancer	0.000428	0.00452	CbGpPWpGaD
Zileuton—Body temperature increased—Sorafenib—thyroid cancer	0.000427	0.00844	CcSEcCtD
Zileuton—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000425	0.00448	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—CALCA—thyroid cancer	0.000412	0.00435	CbGpPWpGaD
Zileuton—Hypersensitivity—Sorafenib—thyroid cancer	0.000398	0.00787	CcSEcCtD
Zileuton—LTB4R—lymph node—thyroid cancer	0.000397	0.103	CbGeAlD
Zileuton—Pruritus—Sorafenib—thyroid cancer	0.000382	0.00755	CcSEcCtD
Zileuton—Abdominal pain upper—Epirubicin—thyroid cancer	0.000371	0.00733	CcSEcCtD
Zileuton—Diarrhoea—Sorafenib—thyroid cancer	0.000369	0.00731	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—CALCB—thyroid cancer	0.000361	0.0038	CbGpPWpGaD
Zileuton—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000358	0.00377	CbGpPWpGaD
Zileuton—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000358	0.00377	CbGpPWpGaD
Zileuton—Dizziness—Sorafenib—thyroid cancer	0.000357	0.00706	CcSEcCtD
Zileuton—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000356	0.00375	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—HPGD—thyroid cancer	0.000348	0.00367	CbGpPWpGaD
Zileuton—ALOX5—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000347	0.00366	CbGpPWpGaD
Zileuton—Vomiting—Sorafenib—thyroid cancer	0.000343	0.00679	CcSEcCtD
Zileuton—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000343	0.00679	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—TRIM33—thyroid cancer	0.000342	0.0036	CbGpPWpGaD
Zileuton—Rash—Sorafenib—thyroid cancer	0.00034	0.00673	CcSEcCtD
Zileuton—Dermatitis—Sorafenib—thyroid cancer	0.00034	0.00673	CcSEcCtD
Zileuton—Headache—Sorafenib—thyroid cancer	0.000338	0.00669	CcSEcCtD
Zileuton—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000334	0.00352	CbGpPWpGaD
Zileuton—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000326	0.00645	CcSEcCtD
Zileuton—Nausea—Sorafenib—thyroid cancer	0.00032	0.00634	CcSEcCtD
Zileuton—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000316	0.00333	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—TSHR—thyroid cancer	0.000311	0.00328	CbGpPWpGaD
Zileuton—UGT1A9—PPARA activates gene expression—RXRA—thyroid cancer	0.000311	0.00328	CbGpPWpGaD
Zileuton—Jaundice—Epirubicin—thyroid cancer	0.000305	0.00603	CcSEcCtD
Zileuton—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000304	0.00321	CbGpPWpGaD
Zileuton—Urinary tract infection—Epirubicin—thyroid cancer	0.000304	0.00601	CcSEcCtD
Zileuton—Conjunctivitis—Epirubicin—thyroid cancer	0.000304	0.00601	CcSEcCtD
Zileuton—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000302	0.00597	CcSEcCtD
Zileuton—ALOX5—Metabolism—MINPP1—thyroid cancer	0.0003	0.00316	CbGpPWpGaD
Zileuton—UGT1A9—NRF2 pathway—SLC5A5—thyroid cancer	0.000295	0.00311	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—TP53—thyroid cancer	0.000294	0.00309	CbGpPWpGaD
Zileuton—Sinusitis—Epirubicin—thyroid cancer	0.000293	0.0058	CcSEcCtD
Zileuton—EPHX2—lymph node—thyroid cancer	0.000292	0.0755	CbGeAlD
Zileuton—LTB4R—Signaling by GPCR—TSHR—thyroid cancer	0.000283	0.00298	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000282	0.00297	CbGpPWpGaD
Zileuton—Jaundice—Doxorubicin—thyroid cancer	0.000282	0.00558	CcSEcCtD
Zileuton—ALOX5—thyroid gland—thyroid cancer	0.000282	0.0728	CbGeAlD
Zileuton—Urinary tract infection—Doxorubicin—thyroid cancer	0.000281	0.00556	CcSEcCtD
Zileuton—Conjunctivitis—Doxorubicin—thyroid cancer	0.000281	0.00556	CcSEcCtD
Zileuton—Hepatitis—Epirubicin—thyroid cancer	0.000281	0.00555	CcSEcCtD
Zileuton—LTB4R—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000278	0.00293	CbGpPWpGaD
Zileuton—Sinusitis—Doxorubicin—thyroid cancer	0.000271	0.00537	CcSEcCtD
Zileuton—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.00027	0.00284	CbGpPWpGaD
Zileuton—Hepatitis—Doxorubicin—thyroid cancer	0.00026	0.00514	CcSEcCtD
Zileuton—ALOX5—Metabolism—NDUFA13—thyroid cancer	0.000255	0.00269	CbGpPWpGaD
Zileuton—ALOX5—head—thyroid cancer	0.00025	0.0646	CbGeAlD
Zileuton—UGT1A9—NRF2 pathway—RXRA—thyroid cancer	0.000248	0.00261	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—SST—thyroid cancer	0.000242	0.00255	CbGpPWpGaD
Zileuton—Flatulence—Epirubicin—thyroid cancer	0.000241	0.00476	CcSEcCtD
Zileuton—LTB4R—Signaling by GPCR—PTCH1—thyroid cancer	0.00024	0.00253	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—CHST14—thyroid cancer	0.00024	0.00253	CbGpPWpGaD
Zileuton—Tension—Epirubicin—thyroid cancer	0.00024	0.00474	CcSEcCtD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000237	0.0025	CbGpPWpGaD
Zileuton—Nervousness—Epirubicin—thyroid cancer	0.000237	0.0047	CcSEcCtD
Zileuton—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000236	0.00249	CbGpPWpGaD
Zileuton—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000236	0.00249	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—CALCA—thyroid cancer	0.000233	0.00246	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000231	0.00244	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TCF7L1—thyroid cancer	0.000228	0.0024	CbGpPWpGaD
Zileuton—Ill-defined disorder—Epirubicin—thyroid cancer	0.000227	0.00449	CcSEcCtD
Zileuton—Flatulence—Doxorubicin—thyroid cancer	0.000223	0.00441	CcSEcCtD
Zileuton—Tension—Doxorubicin—thyroid cancer	0.000222	0.00439	CcSEcCtD
Zileuton—Malaise—Epirubicin—thyroid cancer	0.00022	0.00436	CcSEcCtD
Zileuton—LTB4R—Signaling by GPCR—SST—thyroid cancer	0.00022	0.00232	CbGpPWpGaD
Zileuton—Nervousness—Doxorubicin—thyroid cancer	0.00022	0.00435	CcSEcCtD
Zileuton—UGT1A9—Biological oxidations—RXRA—thyroid cancer	0.000217	0.00229	CbGpPWpGaD
Zileuton—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000216	0.00228	CbGpPWpGaD
Zileuton—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000215	0.00227	CbGpPWpGaD
Zileuton—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	0.000214	0.00226	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—CALCA—thyroid cancer	0.000212	0.00223	CbGpPWpGaD
Zileuton—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00021	0.00415	CcSEcCtD
Zileuton—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.00021	0.00221	CbGpPWpGaD
Zileuton—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000208	0.00219	CbGpPWpGaD
Zileuton—Myalgia—Epirubicin—thyroid cancer	0.000208	0.00412	CcSEcCtD
Zileuton—Chest pain—Epirubicin—thyroid cancer	0.000208	0.00412	CcSEcCtD
Zileuton—Arthralgia—Epirubicin—thyroid cancer	0.000208	0.00412	CcSEcCtD
Zileuton—Discomfort—Epirubicin—thyroid cancer	0.000206	0.00407	CcSEcCtD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000204	0.00215	CbGpPWpGaD
Zileuton—Malaise—Doxorubicin—thyroid cancer	0.000204	0.00403	CcSEcCtD
Zileuton—EPHX2—Metabolism—TPR—thyroid cancer	0.0002	0.00211	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PRKAR1A—thyroid cancer	0.000197	0.00207	CbGpPWpGaD
Zileuton—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	0.000196	0.00207	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—HPGD—thyroid cancer	0.000193	0.00204	CbGpPWpGaD
Zileuton—Arthralgia—Doxorubicin—thyroid cancer	0.000192	0.00381	CcSEcCtD
Zileuton—Myalgia—Doxorubicin—thyroid cancer	0.000192	0.00381	CcSEcCtD
Zileuton—Chest pain—Doxorubicin—thyroid cancer	0.000192	0.00381	CcSEcCtD
Zileuton—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000192	0.00202	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—CDK1—thyroid cancer	0.000192	0.00202	CbGpPWpGaD
Zileuton—Discomfort—Doxorubicin—thyroid cancer	0.00019	0.00376	CcSEcCtD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000188	0.00199	CbGpPWpGaD
Zileuton—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000185	0.00195	CbGpPWpGaD
Zileuton—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000184	0.00194	CbGpPWpGaD
Zileuton—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000182	0.0036	CcSEcCtD
Zileuton—Insomnia—Epirubicin—thyroid cancer	0.00018	0.00357	CcSEcCtD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000178	0.00188	CbGpPWpGaD
Zileuton—Somnolence—Epirubicin—thyroid cancer	0.000177	0.00351	CcSEcCtD
Zileuton—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000177	0.00187	CbGpPWpGaD
Zileuton—Dyspepsia—Epirubicin—thyroid cancer	0.000176	0.00347	CcSEcCtD
Zileuton—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000175	0.00185	CbGpPWpGaD
Zileuton—ALOX5—lymph node—thyroid cancer	0.000175	0.0452	CbGeAlD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000174	0.00183	CbGpPWpGaD
Zileuton—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000172	0.00341	CcSEcCtD
Zileuton—Pain—Epirubicin—thyroid cancer	0.000171	0.00337	CcSEcCtD
Zileuton—Constipation—Epirubicin—thyroid cancer	0.000171	0.00337	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000168	0.00333	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—TSHR—thyroid cancer	0.000167	0.00176	CbGpPWpGaD
Zileuton—Insomnia—Doxorubicin—thyroid cancer	0.000167	0.0033	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—PRKAR1A—thyroid cancer	0.000164	0.00173	CbGpPWpGaD
Zileuton—Feeling abnormal—Epirubicin—thyroid cancer	0.000164	0.00325	CcSEcCtD
Zileuton—Somnolence—Doxorubicin—thyroid cancer	0.000164	0.00325	CcSEcCtD
Zileuton—Dyspepsia—Doxorubicin—thyroid cancer	0.000162	0.00321	CcSEcCtD
Zileuton—UGT1A9—Metabolism—MINPP1—thyroid cancer	0.00016	0.00168	CbGpPWpGaD
Zileuton—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000159	0.00315	CcSEcCtD
Zileuton—Urticaria—Epirubicin—thyroid cancer	0.000158	0.00313	CcSEcCtD
Zileuton—Pain—Doxorubicin—thyroid cancer	0.000158	0.00312	CcSEcCtD
Zileuton—Constipation—Doxorubicin—thyroid cancer	0.000158	0.00312	CcSEcCtD
Zileuton—Body temperature increased—Epirubicin—thyroid cancer	0.000158	0.00312	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—MEN1—thyroid cancer	0.000157	0.00166	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000157	0.00165	CbGpPWpGaD
Zileuton—Feeling abnormal—Doxorubicin—thyroid cancer	0.000152	0.00301	CcSEcCtD
Zileuton—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.00015	0.00159	CbGpPWpGaD
Zileuton—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00015	0.00158	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—SLC5A5—thyroid cancer	0.00015	0.00158	CbGpPWpGaD
Zileuton—Hypersensitivity—Epirubicin—thyroid cancer	0.000147	0.00291	CcSEcCtD
Zileuton—Urticaria—Doxorubicin—thyroid cancer	0.000147	0.0029	CcSEcCtD
Zileuton—Body temperature increased—Doxorubicin—thyroid cancer	0.000146	0.00289	CcSEcCtD
Zileuton—PTGS1—trachea—thyroid cancer	0.000143	0.0369	CbGeAlD
Zileuton—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000143	0.0015	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—PTCH1—thyroid cancer	0.000142	0.0015	CbGpPWpGaD
Zileuton—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000142	0.0015	CbGpPWpGaD
Zileuton—Pruritus—Epirubicin—thyroid cancer	0.000141	0.00279	CcSEcCtD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.00014	0.00148	CbGpPWpGaD
Zileuton—Diarrhoea—Epirubicin—thyroid cancer	0.000136	0.0027	CcSEcCtD
Zileuton—Hypersensitivity—Doxorubicin—thyroid cancer	0.000136	0.00269	CcSEcCtD
Zileuton—UGT1A9—Metabolism—NDUFA13—thyroid cancer	0.000136	0.00143	CbGpPWpGaD
Zileuton—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000132	0.00139	CbGpPWpGaD
Zileuton—Dizziness—Epirubicin—thyroid cancer	0.000132	0.00261	CcSEcCtD
Zileuton—Pruritus—Doxorubicin—thyroid cancer	0.000131	0.00258	CcSEcCtD
Zileuton—CYP1A2—thyroid gland—thyroid cancer	0.00013	0.0337	CbGeAlD
Zileuton—PTGS1—Metabolism—MINPP1—thyroid cancer	0.00013	0.00137	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—SST—thyroid cancer	0.00013	0.00137	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CHST14—thyroid cancer	0.000128	0.00135	CbGpPWpGaD
Zileuton—Vomiting—Epirubicin—thyroid cancer	0.000127	0.00251	CcSEcCtD
Zileuton—Diarrhoea—Doxorubicin—thyroid cancer	0.000126	0.0025	CcSEcCtD
Zileuton—Rash—Epirubicin—thyroid cancer	0.000126	0.00249	CcSEcCtD
Zileuton—EPHX2—Metabolism—RXRA—thyroid cancer	0.000126	0.00132	CbGpPWpGaD
Zileuton—Dermatitis—Epirubicin—thyroid cancer	0.000126	0.00249	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—CALCA—thyroid cancer	0.000125	0.00132	CbGpPWpGaD
Zileuton—Headache—Epirubicin—thyroid cancer	0.000125	0.00247	CcSEcCtD
Zileuton—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000124	0.00131	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000122	0.00129	CbGpPWpGaD
Zileuton—Dizziness—Doxorubicin—thyroid cancer	0.000122	0.00241	CcSEcCtD
Zileuton—Nausea—Epirubicin—thyroid cancer	0.000118	0.00234	CcSEcCtD
Zileuton—Vomiting—Doxorubicin—thyroid cancer	0.000117	0.00232	CcSEcCtD
Zileuton—Rash—Doxorubicin—thyroid cancer	0.000116	0.0023	CcSEcCtD
Zileuton—Dermatitis—Doxorubicin—thyroid cancer	0.000116	0.0023	CcSEcCtD
Zileuton—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000116	0.00122	CbGpPWpGaD
Zileuton—Headache—Doxorubicin—thyroid cancer	0.000116	0.00229	CcSEcCtD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000114	0.0012	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CDK1—thyroid cancer	0.000113	0.00119	CbGpPWpGaD
Zileuton—PTGS1—thyroid gland—thyroid cancer	0.000113	0.0292	CbGeAlD
Zileuton—ALOX5—Metabolism—TPR—thyroid cancer	0.000111	0.00117	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000111	0.00117	CbGpPWpGaD
Zileuton—Nausea—Doxorubicin—thyroid cancer	0.00011	0.00217	CcSEcCtD
Zileuton—ALOX5—Metabolism—PRKAR1A—thyroid cancer	0.000109	0.00115	CbGpPWpGaD
Zileuton—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000106	0.00112	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CHST14—thyroid cancer	0.000104	0.0011	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—HPGD—thyroid cancer	0.000103	0.00108	CbGpPWpGaD
Zileuton—PTGS1—head—thyroid cancer	0.0001	0.0259	CbGeAlD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	9.91e-05	0.00104	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.9e-05	0.00104	CbGpPWpGaD
Zileuton—CYP2C9—Biological oxidations—RXRA—thyroid cancer	9.32e-05	0.000982	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—NRG1—thyroid cancer	9.08e-05	0.000957	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	8.84e-05	0.000931	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.46e-05	0.000892	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—HPGD—thyroid cancer	8.39e-05	0.000884	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.35e-05	0.00088	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—SLC5A5—thyroid cancer	8.32e-05	0.000877	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TERT—thyroid cancer	8.16e-05	0.00086	CbGpPWpGaD
Zileuton—CYP1A2—Biological oxidations—RXRA—thyroid cancer	7.96e-05	0.000839	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PPARG—thyroid cancer	7.93e-05	0.000836	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—HIF1A—thyroid cancer	7.8e-05	0.000822	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	7.79e-05	0.000821	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	7.6e-05	0.000801	CbGpPWpGaD
Zileuton—PTGS1—lymph node—thyroid cancer	7.02e-05	0.0182	CbGeAlD
Zileuton—ALOX5—Metabolism—RXRA—thyroid cancer	6.99e-05	0.000737	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—NRAS—thyroid cancer	6.87e-05	0.000724	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—MINPP1—thyroid cancer	6.84e-05	0.000721	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.8e-05	0.000717	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	6.8e-05	0.000716	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	6.46e-05	0.000681	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—BRAF—thyroid cancer	6.46e-05	0.000681	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PTGS2—thyroid cancer	6.24e-05	0.000658	CbGpPWpGaD
Zileuton—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.14e-05	0.000647	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—KRAS—thyroid cancer	5.91e-05	0.000623	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—TPR—thyroid cancer	5.91e-05	0.000623	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—MINPP1—thyroid cancer	5.85e-05	0.000616	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—NDUFA13—thyroid cancer	5.82e-05	0.000613	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	5.81e-05	0.000613	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CHST14—thyroid cancer	5.47e-05	0.000577	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PTEN—thyroid cancer	5.44e-05	0.000574	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.27e-05	0.000555	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—HRAS—thyroid cancer	5.03e-05	0.00053	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—NDUFA13—thyroid cancer	4.97e-05	0.000524	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—AKT1—thyroid cancer	4.89e-05	0.000515	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—TPR—thyroid cancer	4.82e-05	0.000508	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PRKAR1A—thyroid cancer	4.74e-05	0.0005	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CCND1—thyroid cancer	4.71e-05	0.000497	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CHST14—thyroid cancer	4.68e-05	0.000493	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—PTEN—thyroid cancer	4.55e-05	0.00048	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.51e-05	0.000476	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—AKT1—thyroid cancer	4.44e-05	0.000468	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—SLC5A5—thyroid cancer	4.42e-05	0.000466	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PPARG—thyroid cancer	4.41e-05	0.000465	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—HPGD—thyroid cancer	4.41e-05	0.000465	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.3e-05	0.000453	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.15e-05	0.000437	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—NRAS—thyroid cancer	4.06e-05	0.000428	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.84e-05	0.000404	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—HPGD—thyroid cancer	3.77e-05	0.000397	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—RXRA—thyroid cancer	3.72e-05	0.000392	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.62e-05	0.000381	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CHST14—thyroid cancer	3.61e-05	0.00038	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—SLC5A5—thyroid cancer	3.61e-05	0.00038	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.58e-05	0.000377	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—KRAS—thyroid cancer	3.49e-05	0.000368	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PTGS2—thyroid cancer	3.47e-05	0.000366	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.38e-05	0.000356	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—AKT1—thyroid cancer	3.14e-05	0.000331	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TP53—thyroid cancer	3.11e-05	0.000327	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.06e-05	0.000322	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—RXRA—thyroid cancer	3.03e-05	0.000319	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PTEN—thyroid cancer	3.03e-05	0.000319	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—HRAS—thyroid cancer	2.97e-05	0.000313	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.95e-05	0.000311	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—HPGD—thyroid cancer	2.91e-05	0.000307	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—AKT1—thyroid cancer	2.62e-05	0.000276	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—TPR—thyroid cancer	2.53e-05	0.000267	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.49e-05	0.000263	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PPARG—thyroid cancer	2.35e-05	0.000247	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.26e-05	0.000238	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—TPR—thyroid cancer	2.16e-05	0.000228	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.13e-05	0.000224	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.93e-05	0.000203	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PPARG—thyroid cancer	1.91e-05	0.000202	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.9e-05	0.0002	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PTGS2—thyroid cancer	1.85e-05	0.000195	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.78e-05	0.000187	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—AKT1—thyroid cancer	1.74e-05	0.000184	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—TPR—thyroid cancer	1.67e-05	0.000176	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.64e-05	0.000173	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.62e-05	0.000171	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PTEN—thyroid cancer	1.61e-05	0.00017	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—RXRA—thyroid cancer	1.59e-05	0.000168	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.55e-05	0.000163	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.52e-05	0.00016	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PTGS2—thyroid cancer	1.51e-05	0.000159	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—RXRA—thyroid cancer	1.36e-05	0.000143	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.32e-05	0.00014	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PTEN—thyroid cancer	1.31e-05	0.000138	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.25e-05	0.000132	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—RXRA—thyroid cancer	1.05e-05	0.000111	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PPARG—thyroid cancer	1.01e-05	0.000106	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—AKT1—thyroid cancer	9.28e-06	9.78e-05	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PPARG—thyroid cancer	8.6e-06	9.06e-05	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PTGS2—thyroid cancer	7.91e-06	8.34e-05	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—AKT1—thyroid cancer	7.56e-06	7.97e-05	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PTEN—thyroid cancer	6.9e-06	7.27e-05	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PTGS2—thyroid cancer	6.76e-06	7.13e-05	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PPARG—thyroid cancer	6.63e-06	6.99e-05	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PTEN—thyroid cancer	5.9e-06	6.21e-05	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.22e-06	5.5e-05	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PTEN—thyroid cancer	4.55e-06	4.8e-05	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—AKT1—thyroid cancer	3.98e-06	4.19e-05	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—AKT1—thyroid cancer	3.4e-06	3.58e-05	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—AKT1—thyroid cancer	2.62e-06	2.76e-05	CbGpPWpGaD
